Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Polycythemia Vera (PV)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01291784
What this trial is testing

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more
John Mascarenhas 3
Not applicableNot Yet RecruitingNCT07734272
What this trial is testing

Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative

Who this might be right for
Polycythemia Vera
Massachusetts General Hospital 32
Testing effectiveness (Phase 2)UnknownNCT01298934
What this trial is testing

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis
Ronald Hoffman 22
Testing effectiveness (Phase 2)Study completedNCT04182100
What this trial is testing

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Who this might be right for
Polycythemia Vera (PV)
PharmaEssentia Japan K.K. 29
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Not applicableStudy completedNCT02893410
What this trial is testing

Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients

Who this might be right for
Polycythemia VeraEssential Thrombocythemia
University Hospital, Brest 286
Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Not applicableStudy completedNCT01816256
What this trial is testing

Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms

Who this might be right for
Myeloproliferative Neoplasms (MPN)Polycythemia Vera (PV)Essential Thrombocythemia (ET)+1 more
University Health Network, Toronto 102
Not applicableActive Not RecruitingNCT06798805
What this trial is testing

Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms

Who this might be right for
Essential Thrombocythemia (ET)Myelofibrosis (MF)Polycythemia Vera (PV)
IRCCS Azienda Ospedaliero-Universitaria di Bologna 110
Not applicableStudy completedNCT05421104
What this trial is testing

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Who this might be right for
Polycythemia Vera (PV)
Novartis Pharmaceuticals 1,576
Not applicableNot Yet RecruitingNCT06785870
What this trial is testing

EVAluation of Erythrocytosis PRospEctive Cohort STudy

Who this might be right for
ErythrocytosisPolycythemiaPolycythemia Secondary+5 more
Cyrus Hsia 1,500
Not applicableStudy completedNCT00433862
What this trial is testing

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

Who this might be right for
Polycythemia VeraEssential ThrombocytosisIdiopathic Myelofibrosis+2 more
National Institutes of Health Clinical Center (CC) 8
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Early research (Phase 1)UnknownNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Early research (Phase 1)Looking for participantsNCT07012109
What this trial is testing

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)

Who this might be right for
Polycythemia Vera
BeBetter Med Inc 90
Not applicableStudy completedNCT05853445
What this trial is testing

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

Who this might be right for
Polycythemia Vera
Novartis Pharmaceuticals 467
Not applicableUnknownNCT06251102
What this trial is testing

Real-world Ruxolitinib Experience in PV

Who this might be right for
Polycythemia Vera
Gruppo Italiano Malattie EMatologiche dell'Adulto 153
Testing effectiveness (Phase 2)Study completedNCT00255346
What this trial is testing

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesAgnogenic Myeloid Metaplasia+5 more
M.D. Anderson Cancer Center 68
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Next Page